Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

6.65

Margin Of Safety %

Put/Call OI Ratio

0.4

EPS Next Q Diff

0.03

EPS Last/This Y

-0.27

EPS This/Next Y

0.48

Price

4.84

Target Price

10.29

Analyst Recom

1

Performance Q

-12.95

Relative Volume

0.59

Beta

1.35

Ticker: ALDX




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19ALDX4.860.421.3727046
2024-12-20ALDX4.870.420.5027087
2024-12-23ALDX4.80.410.0525189
2024-12-24ALDX4.760.414.2525165
2024-12-26ALDX5.030.420.5525271
2024-12-27ALDX4.940.420.0925582
2024-12-30ALDX5.020.420.0425584
2024-12-31ALDX5.010.420.2125590
2025-01-02ALDX5.230.420.2125666
2025-01-03ALDX5.450.420.1025718
2025-01-06ALDX5.270.420.1325715
2025-01-07ALDX5.110.411.0026085
2025-01-08ALDX5.110.410.1026217
2025-01-09ALDX5.110.410.1026217
2025-01-10ALDX4.950.400.0326639
2025-01-13ALDX4.770.400.1726661
2025-01-14ALDX4.70.400.1026930
2025-01-15ALDX5.030.400.2427050
2025-01-16ALDX4.780.400.2827530
2025-01-17ALDX4.840.400.0627544
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19ALDX4.86-185.4- -0.91
2024-12-20ALDX4.88-185.4- -0.91
2024-12-23ALDX4.79-171.6- -0.91
2024-12-24ALDX4.76-171.6- -0.91
2024-12-26ALDX5.02-171.6- -0.91
2024-12-27ALDX4.95-171.6- -0.91
2024-12-30ALDX5.02-171.6- -0.91
2024-12-31ALDX5.00-171.6- -0.91
2025-01-02ALDX5.22-171.6- -0.91
2025-01-03ALDX5.45-171.6- -0.91
2025-01-06ALDX5.28-171.6- -0.91
2025-01-07ALDX5.11-171.6- -0.91
2025-01-08ALDX5.11-171.6- -0.91
2025-01-09ALDX5.11-171.6- -0.91
2025-01-10ALDX4.94-171.6- -0.91
2025-01-13ALDX4.78-171.6- -0.91
2025-01-14ALDX4.71-171.6- -0.91
2025-01-15ALDX5.03-171.6- -0.91
2025-01-16ALDX4.79-171.6- -0.91
2025-01-17ALDX4.84-171.6- -0.91
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19ALDX-1.485.585.90
2024-12-20ALDX-1.485.585.90
2024-12-23ALDX-1.474.795.90
2024-12-24ALDX-1.474.795.90
2024-12-26ALDX-1.494.796.13
2024-12-27ALDX-1.484.796.13
2024-12-30ALDX-1.504.906.13
2024-12-31ALDX-1.504.906.13
2025-01-02ALDX-1.494.906.13
2025-01-03ALDX-1.484.906.13
2025-01-06ALDX-1.424.906.13
2025-01-07ALDX-1.424.906.13
2025-01-08ALDX-1.484.906.13
2025-01-09ALDX-1.484.906.13
2025-01-10ALDX-1.484.906.13
2025-01-13ALDX-1.484.916.65
2025-01-14ALDX-1.484.916.65
2025-01-15ALDX-1.484.916.65
2025-01-16ALDX-1.484.916.65
2025-01-17ALDX-1.484.916.65
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.25

Avg. EPS Est. Current Quarter

-0.22

Avg. EPS Est. Next Quarter

-0.22

Insider Transactions

-1.48

Institutional Transactions

4.91

Beta

1.35

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

14

Growth Score

21

Sentiment Score

12

Actual DrawDown %

69.7

Max Drawdown 5-Year %

-90.1

Target Price

10.29

P/E

Forward P/E

PEG

P/S

P/B

3.39

P/Free Cash Flow

EPS

-0.75

Average EPS Est. Cur. Y​

-0.91

EPS Next Y. (Est.)

-0.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.59

Return on Equity vs Sector %

-71.7

Return on Equity vs Industry %

-59.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Aldeyra Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 9
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
stock quote shares ALDX – Aldeyra Therapeutics, Inc. Stock Price stock today
news today ALDX – Aldeyra Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALDX – Aldeyra Therapeutics, Inc. yahoo finance google finance
stock history ALDX – Aldeyra Therapeutics, Inc. invest stock market
stock prices ALDX premarket after hours
ticker ALDX fair value insiders trading